Ownership and insider activity for Marker Therapeutics, Inc. (MRKR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology.
Price
| Price | $1.14 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2025-11-17 | Knobil Katharine | A-Award | 137,330 | $131K |
| 2025-11-17 | Knobil Katharine | A-Award | 84,411 | $81K |
| 2025-11-17 | Eansor Norman David | A-Award | 137,330 | $131K |
| 2025-11-17 | Eansor Norman David | A-Award | 84,411 | $81K |
| 2025-11-17 | ELMS STEVE | A-Award | 137,330 | $131K |
| 2025-11-17 | ELMS STEVE | A-Award | 84,411 | $81K |
| 2025-10-31 | Corzo Kathryn Penkus | A-Award | 147,611 | $146K |
| 2025-10-31 | Vera Juan | A-Award | 250,000 | $247K |
| 2025-10-31 | Corzo Kathryn Penkus | |||
| 2025-02-12 | ELMS STEVE | A-Award | 30,000 | $48K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.9M | $5.1M | $61.7M | $43.9M | $21.4M | $42.4M | $11.8M | $15.1M | $19.2M | $16.1M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | $108177 | $56189 | $1.0M | $237 | $2.4M | $1.0M | $2.3M | $1.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -$988126 | 0 | 0 |
| Total Current Assets | $7.9M | $5.2M | $62.0M | $45.5M | $24.4M | $46.0M | $16.6M | $17.1M | $22.0M | $19.1M |
| Property, Plant & Equipment | 0 | 0 | $148000 | $872702 | $21.2M | $22.2M | $17.8M | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $7.9M | $5.2M | $62.1M | $46.4M | $45.6M | $68.1M | $34.4M | $17.1M | $22.0M | $19.1M |
| Accounts Payable | $680000 | $1.0M | $1.6M | $993000 | $2.9M | $5.1M | $1.1M | $961000 | $1.1M | $793727 |
| Short-term Debt | $5000 | $5000 | 0 | $204132 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.7M | $1.5M | $2.8M | $2.0M | $6.4M | $12.9M | $7.8M | $3.1M | $3.5M | $2.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.7M | $1.5M | $2.8M | $2.3M | $18.3M | $24.1M | $14.8M | $3.1M | $3.5M | $2.3M |
| Retained Earnings | -$145.8M | -$157.4M | -$306.1M | -$327.5M | -$356.2M | -$398.1M | -$428.0M | -$436.3M | -$447.0M | -$459.2M |
| Total Equity | $6.2M | $3.7M | $59.3M | $44.1M | $27.3M | $44.0M | $19.6M | $14.1M | $18.6M | $16.8M |
| Total Debt | $5000 | $5000 | 0 | $484379 | $12.3M | $11.9M | $7.6M | 0 | 0 | 0 |
| Net Debt | -$7.8M | -$5.1M | -$61.7M | -$43.4M | -$9.1M | -$30.5M | -$4.2M | -$15.1M | -$19.2M | -$16.1M |
| Working Capital | $6.2M | $3.7M | $59.2M | $43.5M | $18.0M | $33.1M | $8.8M | $14.1M | $18.6M | $16.8M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 6.03 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -32.65 |
Profitability
| Return on Equity | -72.42% |
| Return on Invested Capital | -76.65% |
| Return on Assets | -63.78% |
| Gross Margin | -320.83% |
| Operating Margin | -868.95% |
| Net Margin | -706.23% |
Related companies: AEON · BOLT · CLRB · COCP · EVGN · GLTO · IMNN
Explore sector: Healthcare · Biotechnology
More sections of MRKR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks